Hernández-Novoa B - Search Results

1

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández MÁ, Moreno S. Gutiérrez C, et al. PLoS One. 2011;6(12):e27864. doi: 10.1371/journal.pone.0027864. Epub 2011 Dec 8. PLoS One. 2011. PMID: 22174752 Free PMC article. Clinical Trial.

2

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S. Vallejo A, et al. AIDS. 2012 Sep 24;26(15):1885-94. doi: 10.1097/QAD.0b013e3283584521. AIDS. 2012. PMID: 22992577 Clinical Trial.

3

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

Serrano-Villar S, Gutiérrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad Fernández M, Madrid N, Dronda F, Zamora J, Muñoz-Fernández MÁ, Moreno S. Serrano-Villar S, et al. J Infect. 2013 Jan;66(1):57-66. doi: 10.1016/j.jinf.2012.09.013. Epub 2012 Oct 6. J Infect. 2013. PMID: 23046968

4

Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.

Abad-Fernández M, Vallejo A, Hernández-Novoa B, Díaz L, Gutiérrez C, Madrid N, Muñoz MA, Moreno S. Abad-Fernández M, et al. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):149-53. doi: 10.1097/QAI.0b013e31829a2f12. J Acquir Immune Defic Syndr. 2013. PMID: 24047967 Clinical Trial.

5

Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.

Gutiérrez C, Hernández-Novoa B, Vallejo A, Serrano-Villar S, Abad-Fernández M, Madrid N, Díaz L, Moreno A, Dronda F, Zamora J, Muñoz-Fernández MA, Moreno S. Gutiérrez C, et al. AIDS. 2013 Aug 24;27(13):2081-8. doi: 10.1097/QAD.0b013e328361d0e1. AIDS. 2013. PMID: 24384589 Clinical Trial.

6

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.

Hernández-Novoa B, Madrid-Elena N, Dronda F, Pérez-Elias MJ, Casado JL, Pérez-Molina JA, Moreno A, Estébanez M, González J, Zamora J, Moreno S. Hernández-Novoa B, et al. J Antimicrob Chemother. 2014 Jul;69(7):1916-9. doi: 10.1093/jac/dku059. Epub 2014 Mar 12. J Antimicrob Chemother. 2014. PMID: 24623833 Clinical Trial.

7

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4⁺ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.

Madrid-Elena N, García-Bermejo ML, Serrano-Villar S, Díaz-de Santiago A, Sastre B, Gutiérrez C, Dronda F, Coronel Díaz M, Domínguez E, López-Huertas MR, Hernández-Novoa B, Moreno S. Madrid-Elena N, et al. Among authors: hernandez novoa b. J Virol. 2018 Apr 13;92(9):e01931-17. doi: 10.1128/JVI.01931-17. Print 2018 May 1. J Virol. 2018. PMID: 29444937 Free PMC article.

8

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.

López-Huertas MR, Gutiérrez C, Madrid-Elena N, Hernández-Novoa B, Olalla-Sierra J, Plana M, Delgado R, Rubio R, Muñoz-Fernández MÁ, Moreno S. López-Huertas MR, et al. Among authors: hernandez novoa b. Sci Rep. 2020 Dec 18;10(1):22286. doi: 10.1038/s41598-020-79002-w. Sci Rep. 2020. PMID: 33339855 Free PMC article.

9

Expression of gut-homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV-1-infected patients?

Abad-Fernández M, Gutiérrez C, Madrid N, Hernández-Novoa B, Díaz L, Muñoz-Fernández MA, Moreno S, Vallejo A. Abad-Fernández M, et al. HIV Med. 2015 Jan;16(1):15-23. doi: 10.1111/hiv.12167. Epub 2014 May 15. HIV Med. 2015. PMID: 24831847 Free article.

10

The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.

Rodriguez JM, Hermida JM, Casado JL, Quereda C, Moreno A, Dronda F, Hernandez-Novoa B, Rodriguez MA, Perez-Elias MJ, Moreno S. Rodriguez JM, et al. AIDS. 2011 Apr 24;25(7):1006-9. doi: 10.1097/QAD.0b013e3283466f85. AIDS. 2011. PMID: 21422988

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters